JP Morgan Chase
LGND icon

JP Morgan Chase’s Ligand Pharmaceuticals LGND Stock Holding History

JP Morgan Chase’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,412
Closed -$357K – 6676
2022
Q2 		$357K Buy
+6,412
New +$364K ﹤0.01% 4755
2020
Q2 		– Sell
-3,527
Closed -$160K – 5550
2020
Q1 		$160K Buy
+3,527
New +$200K ﹤0.01% 4356
2019
Q1 		– Sell
-561,050
Closed -$47.5M – 5921
2018
Q4 		$47.5M Buy
+561,050
New +$59.8M 0.01% 920
2017
Q2 		– Sell
-43,281
Closed -$2.86M – 5091
2017
Q1 		$2.86M Sell
43,281
-24,045
-36% -$1.58M ﹤0.01% 2813
2016
Q4 		$4.27M Buy
+67,326
New +$4.25M ﹤0.01% 2580

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's LGND Position: Q2 2026 in Review

JP Morgan Chase reduced its Ligand Pharmaceuticals (LGND) stake by 15% in Q2 2026, selling an estimated $3.12M and leaving 73,052 shares worth $23.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2097.

JP Morgan Chase first reported a position in LGND in Q2 2013 and has held it in 46 quarters since. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • JP Morgan Chase held 73,052 shares of Ligand Pharmaceuticals worth $23.2M as of Q2 2026.
  • JP Morgan Chase sold 13,222 Ligand Pharmaceuticals shares in Q2 2026, an estimated $3.12M.
  • Ligand Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2097 holding.
  • JP Morgan Chase first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 46 quarters since.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.